Granules India has submitted a Paragraph IV filing for Ruxolitinib Extended-Release Tablets in the US, aiming for 180-day generic exclusivity. This move is part of the company's strategic pivot toward high-value, complex products. Supported by a strong cash position after a recent ₹1,093 crore capital infusion, the firm is now expanding its capacity while navigating the regulatory and legal challenges inherent in such filings.
Hyderabad-based drugmaker Granules India has submitted a Paragraph IV certification with the US Food and Drug Administration (FDA) for its Ruxolitinib Extended-Release Tablets. By taking this regulatory step, the company is aiming to become the first generic manufacturer to launch this medicine in the United States. If successful, this 'first-to-file' status could grant the company 180 days of exclusive marketing rights, providing a significant competitive advantage.
This filing is a key element of the company’s broader 'Granules 2.0' strategy, which focuses on moving away from low-margin, commodity-based drugs toward high-value, complex, and specialty products. This transition is already showing results, with complex products contributing to nearly 33% of the company’s revenue in the 2026 financial year. The company is investing heavily in this direction, with a ₹2,000 crore organic capital expenditure plan spanning the next three to four years to bolster its capabilities in peptide CDMO, oncology, and complex generics.
Financially, Granules India is well-positioned to fund these initiatives. Following a ₹1,093 crore promoter warrant conversion completed in September 2026, the company currently holds a net cash surplus. This financial stability provides the resources needed to undertake the expensive and long-term processes required for complex drug development and regulatory filings.
However, the path to generic exclusivity is complex and fraught with uncertainty. A Paragraph IV filing involves challenging existing patents held by the innovator company, which often leads to legal battles and extended litigation. Additionally, FDA approval is never guaranteed, and the timeline for such applications is subject to federal scrutiny and administrative reviews. Beyond legal hurdles, there is an execution risk involved in scaling up the manufacturing facilities required for high-complexity drugs. The company must also contend with the intense pricing competition that is typical in the US generic market.
For investors, the most important update to monitor will be the outcome of the US FDA’s review process and any developments regarding potential patent challenges from the originator. The success of this move will depend not only on regulatory clearance but also on the company’s ability to efficiently manufacture and scale the product to meet market demand, while managing the costs and risks of potential litigation.